Gilbarco Veeder-Root, a wholly owned unit of Danaher Corporation (DHR), agreed to buy a petroleum dispensing pump (PDP) unit from Larsen & Toubro (L&T) in India. The PDP business unit manufactures, sells, integrates and services petroleum dispensers, LPG equipment, and automation systems solutions. The financial terms of the acquisition were not disclosed.   This acquisition will further strengthen Gilbarco’s position in the fast growing Indian market. Danaher’s management stated that the acquisition reaffirms the company’s interest in India and is in tandem with its long-term growth strategy. The acquired unit will be joining 14 other Danaher companies in India.   The PDP unit will be a part of Gilbarco Veeder-Root’s organization in a new division called Gilbarco Veeder-Root India. Gilbarco supplies integrated fuel control, site management and support services for petroleum marketers and commercial fuelling enterprises.   During its third quarter conference call, Danaher pointed that it was ...

Sikorsky Aircraft Corp. and Tata Advanced Systems Ltd. (TASL) today announced creation of a joint venture that will manufacture aerospace components for Sikorsky in India, including components for S-92® helicopter cabins. The joint venture agreement builds upon a long-term contract signed in Jun 2009 for TASL to assemble Sikorsky S-92® helicopter cabins. Sikorsky is a subsidiary of United Technologies Corp. (UTX) and TASL is a wholly owned subsidiary of Tata Sons.

Both the joint venture agreement and the cabin assembly contract stem from a MOU signed in Feb 2007 by the companies to explore the creation of aerospace operations in India. The cabin assembly contract signed in June 2009 has led to ongoing construction in Hyderabad, in the state of Andhra Pradesh, where TASL will assemble S-92 helicopter cabins starting in 2010.  The new joint venture will be positioned to manufacture components for other aerospace Original Equipment Manufacturers

...

This post is a guest contribution by Dr Mark Mobius, executive chairman of Templeton Asset Management.

During 2008, Russia was among the weakest stock market performers in the emerging market universe, losing more than 70% in US$ terms. But this year, the market has staged an impressive rally surging nearly 100% in the year-to-October period. The Russian market is among the cheapest in the emerging market universe and is trading at a discount of around 50% to its counterparts.

Today, Russia and many other emerging markets are now being driven by an excess in money supply in the international markets which means that these markets are experiencing an inflow of money for investments. Consequently, as Russia was more depressed than other markets, the upside is greater. At Templeton, we continue to find attractive opportunities in most sectors despite the recent rally as valuations remain undervalued. The Templeton Emerging

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Sunday November 8, 2009

DrStockPick.com Article!

**************************************************************

Let’s call it what it is; It’s Reagan’s Fault!

The government, both state and federal, is on a feeding frenzy to save the banks, the real reason is that the banks are the feeding ground for our politicians, in fact any office seeker is beholden to the banks for their financial support. As such there will never be any meaningful control over these institutions.

There are now 140 fewer banks then there was last year, and the too big to fail have gotten even larger, and now

...

On Monday morning, the Food and Drug Administration panel approved Arzerra, a leukemia treatment that will be marketed and commercialized by GlaxoSmithKline Plc (ADR) (NYSE:GSK). As per the announcement made by the GSK executives, Arzerra is for those patients who have failed to respond to other therapies that cure leukemia. This new drug marketed by GSK was originally developed by GlaxoSmithKline and Genmab A/S, a Danish company. The drug is designed to treat patients with chronic lymphocytic leukemia also known as CLL and for those whose disease has progressed despite previous treatments with other cancer drugs.

GSK is a global healthcare company that is more into the creation and development, manufacturing and marketing of various pharmaceutical products including vaccines and over the counter medicines and other health related

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Tuesday October 27, 2009, are:

**************************************************************

GSK, GlaxoSmithKline plc

GSK, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter medicines, and health related consumer products. GSK operates in two segments, Pharmaceutical and Consumer Healthcare.

** The Food and Drug Administration Monday approved Arzerra, a leukemia treatment that will be marketed by GSK for patients who have failed to respond to other therapies.

More about GSK at www.gsk.com

**************************************************************

EVRN, Everock Inc., EVRN.PK

EVRN produces a line of all-natural gourmet vegetable dips and sandwich spreads marketed under the Nature’s Peak brand.

Both

...

Danaher Corporation (DHR) reported that net earnings for the quarter ended October 2, 2009 were $351 million, or $1.05 per share, a 5.5% decrease as compared to the company’s 2008 third quarter net earnings of $372 million, or $1.11 per share. This was higher than the Zacks Consensus Estimate of 86 cents per share. Sales for the 2009 third quarter were $2.75 billion, 14.5% less than the $3.21 billion reported for the 2008 third quarter. Core revenues declined 14% in the quarter, compared to the third quarter of 2008. Core revenue refers to GAAP revenue from existing businesses and acquired businesses starting from and after the first anniversary of the acquisition. The increase in gross profit margin in the three months ended October 2, 2009 was largely due to year-over-year cost savings generated from the fourth quarter 2008 and 2009 restructuring activities in addition to ...

Pfizer Inc. (PFE) reported third quarter net income of 51 cents per share, which beat the Zacks Consensus Estimate of 48 cents. The company’s net income was 62 cents per share in the year-ago quarter. Revenues for the quarter decreased 3% to $11.6 billion. Revenues for the quarter were unfavorably impacted by approximately 5% due to foreign exchange, and were favorably impacted by 2% due to an adjustment in the third quarter of 2008 for product returns. U.S. revenues, which accounted for 41% of total revenues in the quarter, came in at $4.8 billion, a decrease of 2% compared with the year-ago quarter. International revenues decreased 4% to $6.8 billion, reflecting 5% operational growth and a 9% unfavorable foreign exchange impact. Sales of Pfizer’s mega-blockbuster anti-cholesterol medicine Lipitor fell 9% globally to $2.85 billion in the third quarter. US sales of the drug fell 12%. ...

Companies featured in this edition of the newsletter: CHIP, ENZ, GERS, IWEB, OMCM, ONEZ, XSNX

Markets hit fresh highs for ‘09 yet again last week, as the first round of earnings helped to assuage investor concerns that operating results would underpin robust gains in equities this year. All told, the Dow gained 130 points to end the week at 9995 after briefly cracking the 10,000 mark, gaining 1.3% on the week and extending its gains to 13.9% on the year. The Nasdaq gained 0.8% on the week to close at 2156, up 36.8% on the year, while the S&P 500 and Russell 2000 gained 1.5% and 0.2% respectively, bringing their YTD totals to 20.4% and 23.4%.

Earnings stole the spotlight last week as things got off to a strong start early with JP Morgan handily beating expectations calling for $0.51 per share, reporting earnings of $0.82 per share. Citigroup

...

The deal between Pfizer Inc. (PFE) and Wyeth was completed yesterday after the receipt of final regulatory approvals. Wyeth will cease to trade as an independent entity from today. Under the terms of the deal, Wyeth shareholders will receive $33 cash (without interest) and 0.985 Pfizer shares for every Wyeth share.   The cash-and-stock deal, which was valued at $68 billion when it was announced nine months ago, stood at about $66.9 billion based on Wednesday’s closing prices. Pfizer borrowed about $22.5 billion to this transaction. Pfizer expects the combined companies to realize synergies of about $4 billion by 2012. The deal is expected to be accretive to earnings by the second full-year following closing. Roughly one-half of the savings are expected to come from Selling General & Administrative costs with the balance coming from Research and Development. Pfizer intends to incrementally pay down the debt financing and ...